Announcement PDF Emyria ASX Announcement | 8 September 2026 ASX RELEASE. 8 September 2026 Emyria Set to Launch First Sydney Clinic Following Key Operational Milestones Clinic on-track for opening in Q3 2026, with fit-out finalised, medication and pharmaceutical partners secured, and first cohort of Authorised Prescribers and therapists trained Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in delivering evidence- based intensive mental-health care, is pleased to announce that preparations for the opening of its first Sydney clinic are progressing as planned, with the clinic on track to commence operations in September 2026. Significant operational milestones have now been completed ahead of opening. The Company has recruited and trained ~20 Sydney-based therapists and 4 psychiatrists, establishing the initial clinical team required to support the clinic’s launch.1 Two Sydney psychiatrists have also obtained Authorised Prescriber status, while hospital, pharmacy, medication supply and other key healthcare arrangements have now been secured. The Sydney clinic will establish Emyria’s first presence in New South Wales and represents an important step in the continued expansion of the Company’s national clinical network. With operations already established across Queensland, Victoria and Western Australia, the New South Wales clinic will extend Emyria’s treatment footprint into Australia’s most populous state, providing increased access to specialist mental health care in one of the country’s largest and most important healthcare markets.2 • Sydney clinic fit-out complete – four treatment rooms furnished and equipped ahead of the planned September 2026 opening. • Clinical team established ahead of launch – ~20 Sydney-based therapists and 4 psychiatrists recruited and trained, providing the initial clinical capacity for the new site. • TGA endorsement of first 2 Sydney Authorised Prescribers – supporting Emyria’s ability to commence treatments following opening. • Medication supply and key healthcare partnerships secured – pharmacy and pharmaceutical arrangements in place, alongside a formal agreement with Matilda Nepean Private Hospital. • First patients already approved for treatment – patients approved through the workers compensation pathway are expected to commence treatment shortly after the clinic opens. • Sydney launch expands Emyria into Australia’s largest population market – establishing the Company’s first NSW presence and broadening access to evidence- based mental health treatments amid growing demand. ASX RELEASE. 2 The clinic is now furnished and equipped, with four dedicated treatment rooms available to support patient care. Importantly, the first patients have already been approved for treatment through the workers compensation pathway and are expected to commence treatment shortly following the clinic’s opening. Planned clinic opening coinciding with growing demand for new evidence-based therapies The expansion of Emyria’s national clinic network comes at a time of increasing global interest, clinical validation and investment in psychedelic-assisted therapies and other emerging mental health treatments. Growing policy support, pharmaceutical industry investment and broader institutional interest continue to reinforce the potential role of psychedelic-assisted therapies within the evolving mental health treatment landscape. Recent activity includes Eli Lilly’s acquisition of AtaiBeckley for approximately $3.8 billion3 , Johnson & Johnson leading an $85 million investment in Delix Therapeutics4 , and policy initiatives in the United States aimed at accelerating access to emerging psychedelic-based treatments5 . Together, these developments reflect increasing global recognition of the need for new treatment options for patients who do not achieve adequate outcomes from conventional therapies. Emyria’s expanding clinical network positions the Company to respond to this demand in Australia while continuing to build the clinical infrastructure, practitioner network and patient pathways required to support the delivery of evidence-based intensive mental health treatments. Executive Chairman Greg Hutchinson commented: “We are delighted with the progress being made towards the opening of our first Sydney clinic. With the fit-out complete, our initial clinical team trained, Authorised Prescribers in place and key medication and healthcare partnerships secured, the operational foundations required for launch are now substantially established. “Sydney represents an important expansion of Emyria’s national footprint and provides the Company with a presence in Australia’s largest population market. Importantly, it will create a new pathway for patients across New South Wales seeking access to specialist and evidence-based mental health treatments. References: 1 See ASX release 22 June 2026 2 See ASX release 27 August 2026 3 https://www.bloomberg.com/news/articles/2026-07-16/lilly-to-buy-psychedelic-firm-ataibeckley-for-up-to-3-8-billion 4 https://psychedelicalpha.com/news/scoop-johnson-johnson-to-lead-delix-therapeutics-85m-series-c/ 5 https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following- executive-order This release has been approved by the Board of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 153 355 | investors@emyria.com ASX RELEASE. 3 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs